Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients.

[1]  Jun Yu Li,et al.  Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co‐administered with tacrolimus , 2019, British journal of clinical pharmacology.

[2]  A. Vinks,et al.  Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  Miao Wang,et al.  Metabolic profile elucidation of Zhi–Zi–Da–Huang decoction in rat intestinal bacteria using high-resolution mass spectrometry combined with multiple analytical perspectives , 2019, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  R. Nabbout,et al.  Simulations of Valproate Doses Based on an External Evaluation of Pediatric Population Pharmacokinetic Models , 2018, Journal of clinical pharmacology.

[5]  D. Mager,et al.  Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? , 2018, Journal of clinical pharmacology.

[6]  J. Oh,et al.  CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation , 2018, Therapeutics and clinical risk management.

[7]  Mou-Ze Liu,et al.  Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation , 2018, Current drug metabolism.

[8]  H. Yun,et al.  External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients , 2018, British journal of clinical pharmacology.

[9]  Hao-Qiang Shi,et al.  Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients , 2017, Journal of clinical pharmacy and therapeutics.

[10]  D. Adams,et al.  Model‐based precision dosing of sirolimus in pediatric patients with vascular anomalies , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  D. Mansour,et al.  Biliary Complications in Recipients of Living-Donor Liver Transplant: A Single-Center Review of 120 Patients. , 2017, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[12]  D. Kuypers,et al.  Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. , 2016, British journal of clinical pharmacology.

[13]  S. Dutta,et al.  Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection , 2016, Therapeutic drug monitoring.

[14]  Bruce Green,et al.  The Impact of Model-Misspecification on Model Based Personalised Dosing , 2016, The AAPS Journal.

[15]  S. Vadcharavivad,et al.  Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations , 2016, Journal of clinical pharmacy and therapeutics.

[16]  C. Staatz,et al.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet? , 2016, Clinical Pharmacokinetics.

[17]  Z. Jiao,et al.  External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. , 2016, British journal of clinical pharmacology.

[18]  Jun Seo Park,et al.  Enhanced dissolution and oral absorption of tacrolimus by supersaturable self-emulsifying drug delivery system , 2016, International journal of nanomedicine.

[19]  D. Kuypers,et al.  Clinical determinants of calcineurin inhibitor disposition: a mechanistic review , 2016, Drug metabolism reviews.

[20]  A. Burroughs,et al.  EASL Clinical Practice Guidelines: Liver transplantation. , 2016, Journal of hepatology.

[21]  Yuan Zhang,et al.  Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients , 2015, Xenobiotica; the fate of foreign compounds in biological systems.

[22]  D. Hesselink,et al.  Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. , 2015, Transplantation reviews.

[23]  W. Lu,et al.  A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients , 2014, Acta Pharmacologica Sinica.

[24]  T. Parker,et al.  Transplant Patient Classification and Tacrolimus Assays: More Evidence of the Need for Assay Standardization , 2014, Therapeutic drug monitoring.

[25]  Jiayin Yang,et al.  Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. , 2014, World journal of gastroenterology.

[26]  Y. Zhang,et al.  The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients , 2014, Journal of pharmaceutics.

[27]  B. Caffo,et al.  Practical recommendations for population PK studies with sampling time errors , 2013, European Journal of Clinical Pharmacology.

[28]  E. Suárez,et al.  Tacrolimus dose individualization in "de novo" patients after 10 years of experience in liver transplantation: pharmacokinetic considerations and patient pathophysiology. , 2013, International journal of clinical pharmacology and therapeutics.

[29]  J. Ringers,et al.  Reply to: Asystole to cross‐clamp period predicts development of biliary complications in liver transplantation using donation after cardiac death donors , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[30]  Leena Choi,et al.  Combinational Effect of Intestinal and Hepatic CYP3A5 Genotypes on Tacrolimus Pharmacokinetics in Recipients of Living Donor Liver Transplantation , 2012, Transplantation.

[31]  J. Nguyen,et al.  Asystole to cross‐clamp period predicts development of biliary complications in liver transplantation using donation after cardiac death donors , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[32]  A. Abdollahi,et al.  Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. , 2012, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[33]  Zhi-Hai Peng,et al.  The Impact of Sulfonylureas on Tacrolimus Apparent Clearance Revealed by a Population Pharmacokinetics Analysis in Chinese Adult Liver-Transplant Patients , 2012, Therapeutic drug monitoring.

[34]  Michael B Bolger,et al.  In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. , 2012, Molecular pharmaceutics.

[35]  E. Suárez,et al.  Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction , 2012, European Journal of Clinical Pharmacology.

[36]  M. Karlsson,et al.  Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplantation: Early Posttransplantation Clearance , 2011, Therapeutic drug monitoring.

[37]  A. Israni,et al.  Dosing equation for tacrolimus using genetic variants and clinical factors. , 2011, British journal of clinical pharmacology.

[38]  C. Duvoux,et al.  Evaluation of the Architect tacrolimus assay in kidney, liver, and heart transplant recipients. , 2010, Journal of pharmaceutical and biomedical analysis.

[39]  B. Ploeger,et al.  Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients , 2009, Therapeutic drug monitoring.

[40]  V. Haufroid,et al.  Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.

[41]  D. Hochstrasser,et al.  Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique. , 2008, Clinical biochemistry.

[42]  D. Hommes,et al.  Flexible Limited Sampling Model for Monitoring Tacrolimus in Stable Patients Having Undergone Liver Transplantation With Samples 4 to 6 Hours After Dosing Is Superior to Trough Concentration , 2008, Therapeutic drug monitoring.

[43]  C. Duvoux,et al.  Pharmacokinetic-Pharmacodynamic Assessment of Tacrolimus in Liver-Transplant Recipients during the Early Post-Transplantation Period , 2008, Therapeutic drug monitoring.

[44]  S. Uemoto,et al.  Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients , 2008, Pharmacogenetics and genomics.

[45]  Dan Li,et al.  Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL‐10 polymorphisms in adult liver transplant patients , 2007, Journal of clinical pharmacy and therapeutics.

[46]  K. Suh,et al.  Factors Affecting the Apparent Clearance of Tacrolimus in Korean Adult Liver Transplant Recipients , 2006, Pharmacotherapy.

[47]  Michael B. Bolger,et al.  In Silico Modeling of Non-Linear Drug Absorption for the P-gp Substrate Talinolol and of Consequences for the Resulting Pharmacodynamic Effect , 2006, Pharmaceutical Research.

[48]  S. Chan,et al.  Population Pharmacokinetics of Tacrolimus in Whole Blood and Plasma in Asian Liver Transplant Patients , 2006, Clinical pharmacokinetics.

[49]  Jae Eun Ahn,et al.  Inherent Correlation Between Dose and Clearance in Therapeutic Drug Monitoring Settings: Possible Misinterpretation in Population Pharmacokinetic Analyses , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[50]  A. McLachlan,et al.  Population Pharmacokinetic Estimation of Tacrolimus Apparent Clearance in Adult Liver Transplant Recipients , 2005, Therapeutic drug monitoring.

[51]  S. Urien,et al.  Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance , 2005, European Journal of Clinical Pharmacology.

[52]  L. Yucetin,et al.  Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods. , 2005, Clinical biochemistry.

[53]  C. Staatz,et al.  Sampling Times for Monitoring Tacrolimus in Stable Adult Liver Transplant Recipients , 2004, Therapeutic drug monitoring.

[54]  Siew Bang Cheng,et al.  The EMIT 2000 tacrolimus assay: an application protocol for the Beckman Synchron LX20 PRO analyzer. , 2004, Clinical biochemistry.

[55]  Mats O Karlsson,et al.  Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. , 2004, British journal of clinical pharmacology.

[56]  S. Masuda,et al.  CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. , 2004, Pharmacogenetics.

[57]  Ene I. Ette,et al.  Population Pharmacokinetic Modeling: The Importance of Informative Graphics , 1995, Pharmaceutical Research.

[58]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[59]  S. Uemoto,et al.  Forecasting of Blood Tacrolimus Concentrations Based on the Bayesian Method in Adult Patients Receiving Living-Donor Liver Transplantation , 2003, Clinical pharmacokinetics.

[60]  C. Staatz,et al.  Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[61]  V. Cosson,et al.  Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients , 2003, European Journal of Clinical Pharmacology.

[62]  S. Kaneko,et al.  Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-Glycoprotein after high-dose steroid therapy , 2002, Transplantation.

[63]  W. Weimar,et al.  Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. , 2002, Transplantation proceedings.

[64]  S. Uemoto,et al.  Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. , 2002, The Journal of surgical research.

[65]  G. Amidon,et al.  Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. , 2002, Journal of pharmaceutical sciences.

[66]  U. Christians,et al.  Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus , 2002, Clinical pharmacokinetics.

[67]  H. Saito,et al.  Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation , 2001, European Journal of Clinical Pharmacology.

[68]  I. Bekersky,et al.  Comparative Tacrolimus Pharmacokinetics: Normal versus Mildly Hepatically Impaired Subjects , 2001, Journal of clinical pharmacology.

[69]  P. Wallemacq,et al.  Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult Patients , 2001, Clinical pharmacokinetics.

[70]  S. Chan,et al.  Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. , 2000, British journal of clinical pharmacology.

[71]  J. Boissel,et al.  Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it? , 2000, Journal of pharmaceutical sciences.

[72]  R. Strong.  Whither living donor liver transplantation? , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[73]  W J Jusko,et al.  Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[74]  G. Krejs,et al.  Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. , 1993, Transplantation.

[75]  N. Sigal,et al.  FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. , 1989, Journal of immunology.

[76]  L B Sheiner,et al.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.